Oleclumab (MEDI9447) EGFRm NSCLC Novel Combination Study
Status:
Active, not recruiting
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety, tolerability and antitumor activity
of novel combination therapies administered in subjects with advanced EGFRm NSCLC